vs
ALKAMI TECHNOLOGY, INC.（ALKT）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ALKAMI TECHNOLOGY, INC.的1.6倍（$199.9M vs $126.1M），ALKAMI TECHNOLOGY, INC.净利率更高（-7.9% vs -29.5%，领先21.6%），ALKAMI TECHNOLOGY, INC.同比增速更快（28.9% vs -5.9%），ALKAMI TECHNOLOGY, INC.自由现金流更多（$-7.4M vs $-14.3M），过去两年ALKAMI TECHNOLOGY, INC.的营收复合增速更高（23.9% vs 7.7%）
Alkami科技是一家面向美国市场的云原生数字银行解决方案提供商，主要为社区银行、信用合作社等金融机构提供在线及移动银行系统、支付处理工具、数据分析模块与客户互动功能，助力合作机构优化终端用户的数字银行使用体验。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ALKT vs APLS — 直观对比
营收规模更大
APLS
是对方的1.6倍
$126.1M
营收增速更快
ALKT
高出34.9%
-5.9%
净利率更高
ALKT
高出21.6%
-29.5%
自由现金流更多
ALKT
多$6.9M
$-14.3M
两年增速更快
ALKT
近两年复合增速
7.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $126.1M | $199.9M |
| 净利润 | $-10.0M | $-59.0M |
| 毛利率 | 58.6% | — |
| 营业利润率 | 36.9% | -25.6% |
| 净利率 | -7.9% | -29.5% |
| 营收同比 | 28.9% | -5.9% |
| 净利润同比 | -27.5% | -62.2% |
| 每股收益（稀释后） | — | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKTAPLS
| Q1 26 | $126.1M | — | ||
| Q4 25 | $120.8M | $199.9M | ||
| Q3 25 | $113.0M | $458.6M | ||
| Q2 25 | $112.1M | $178.5M | ||
| Q1 25 | $97.8M | $166.8M | ||
| Q4 24 | $89.7M | $212.5M | ||
| Q3 24 | $85.9M | $196.8M | ||
| Q2 24 | $82.2M | $199.7M |
净利润ALKTAPLS
| Q1 26 | $-10.0M | — | ||
| Q4 25 | — | $-59.0M | ||
| Q3 25 | $-14.8M | $215.7M | ||
| Q2 25 | $-13.6M | $-42.2M | ||
| Q1 25 | — | $-92.2M | ||
| Q4 24 | — | $-36.4M | ||
| Q3 24 | $-9.4M | $-57.4M | ||
| Q2 24 | $-12.3M | $-37.7M |
毛利率ALKTAPLS
| Q1 26 | 58.6% | — | ||
| Q4 25 | 57.2% | — | ||
| Q3 25 | 56.8% | — | ||
| Q2 25 | 58.6% | — | ||
| Q1 25 | 59.0% | — | ||
| Q4 24 | 59.3% | — | ||
| Q3 24 | 58.9% | — | ||
| Q2 24 | 59.4% | — |
营业利润率ALKTAPLS
| Q1 26 | 36.9% | — | ||
| Q4 25 | -7.9% | -25.6% | ||
| Q3 25 | -11.4% | 48.7% | ||
| Q2 25 | -14.2% | -18.6% | ||
| Q1 25 | -15.7% | -50.0% | ||
| Q4 24 | -9.6% | -12.3% | ||
| Q3 24 | -12.1% | -24.0% | ||
| Q2 24 | -16.1% | -14.7% |
净利率ALKTAPLS
| Q1 26 | -7.9% | — | ||
| Q4 25 | — | -29.5% | ||
| Q3 25 | -13.1% | 47.0% | ||
| Q2 25 | -12.1% | -23.6% | ||
| Q1 25 | — | -55.3% | ||
| Q4 24 | — | -17.1% | ||
| Q3 24 | -11.0% | -29.2% | ||
| Q2 24 | -15.0% | -18.9% |
每股收益（稀释后）ALKTAPLS
| Q1 26 | — | — | ||
| Q4 25 | $-0.11 | $-0.40 | ||
| Q3 25 | $-0.14 | $1.67 | ||
| Q2 25 | $-0.13 | $-0.33 | ||
| Q1 25 | $-0.08 | $-0.74 | ||
| Q4 24 | $-0.07 | $-0.30 | ||
| Q3 24 | $-0.09 | $-0.46 | ||
| Q2 24 | $-0.13 | $-0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.4M | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.7M | $370.1M |
| 总资产 | $829.3M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALKTAPLS
| Q1 26 | $40.4M | — | ||
| Q4 25 | $63.5M | $466.2M | ||
| Q3 25 | $57.3M | $479.2M | ||
| Q2 25 | $52.4M | $370.0M | ||
| Q1 25 | $61.7M | $358.4M | ||
| Q4 24 | $94.4M | $411.3M | ||
| Q3 24 | $81.0M | $396.9M | ||
| Q2 24 | $61.4M | $360.1M |
股东权益ALKTAPLS
| Q1 26 | $370.7M | — | ||
| Q4 25 | $362.0M | $370.1M | ||
| Q3 25 | $350.1M | $401.2M | ||
| Q2 25 | $344.0M | $156.3M | ||
| Q1 25 | $334.0M | $164.2M | ||
| Q4 24 | $357.0M | $228.5M | ||
| Q3 24 | $338.5M | $237.1M | ||
| Q2 24 | $327.2M | $264.3M |
总资产ALKTAPLS
| Q1 26 | $829.3M | — | ||
| Q4 25 | $847.2M | $1.1B | ||
| Q3 25 | $835.2M | $1.1B | ||
| Q2 25 | $840.4M | $821.4M | ||
| Q1 25 | $837.2M | $807.3M | ||
| Q4 24 | $437.3M | $885.1M | ||
| Q3 24 | $422.2M | $901.9M | ||
| Q2 24 | $403.9M | $904.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.8M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $-7.4M | $-14.3M |
| 自由现金流率自由现金流/营收 | -5.8% | -7.1% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $40.1M | $45.0M |
8季度趋势，按日历期对齐
经营现金流ALKTAPLS
| Q1 26 | $-4.8M | — | ||
| Q4 25 | $16.6M | $-14.2M | ||
| Q3 25 | $30.8M | $108.5M | ||
| Q2 25 | $1.2M | $4.4M | ||
| Q1 25 | $-5.7M | $-53.4M | ||
| Q4 24 | $6.1M | $19.4M | ||
| Q3 24 | $11.0M | $34.1M | ||
| Q2 24 | $548.0K | $-8.3M |
自由现金流ALKTAPLS
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.2M | $-14.3M | ||
| Q3 25 | $30.5M | $108.3M | ||
| Q2 25 | $760.0K | $4.4M | ||
| Q1 25 | $-6.1M | $-53.4M | ||
| Q4 24 | $6.0M | $19.3M | ||
| Q3 24 | $10.7M | — | ||
| Q2 24 | $123.0K | $-8.4M |
自由现金流率ALKTAPLS
| Q1 26 | -5.8% | — | ||
| Q4 25 | 13.4% | -7.1% | ||
| Q3 25 | 27.0% | 23.6% | ||
| Q2 25 | 0.7% | 2.5% | ||
| Q1 25 | -6.3% | -32.0% | ||
| Q4 24 | 6.6% | 9.1% | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 0.1% | -4.2% |
资本支出强度ALKTAPLS
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.2% | 0.0% | ||
| Q2 25 | 0.4% | 0.0% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 0.2% | 0.0% | ||
| Q3 24 | 0.4% | 0.0% | ||
| Q2 24 | 0.5% | 0.0% |
现金转化率ALKTAPLS
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKT
暂无分部数据
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
